Zepp Health (ZEPP) CFO Cheng Deng Sells 366,000 Shares

Cheng Deng, the Chief Financial Officer of ZEPP, sold 366,000 shares of the company on June 26, 2026. This transaction was not part of a pre-planned sale. The sale comes as several institutional investors adjusted their holdings in ZEPP.

Other Institutional Activity in ZEPP

FIL LTD increased its holdings in ZEPP by 91,596 shares, bringing its total to 717,352 shares valued at approximately $8.57 million. Morgan Stanley also grew its position, adding 97,397 shares to hold a total of 707,691 shares worth about $8.46 million. In contrast, Point72 Asset Management, L.P. slightly reduced its stake by 294 shares, ending with 577,676 shares valued at $6.90 million. Millennium Management LLC cut its holdings by 24,322 shares, resulting in 342,504 shares worth $4.09 million. Meanwhile, Monolith Management LTD expanded its stake significantly by 40,182 shares, now holding 173,847 shares valued at $2.08 million.

Zepp Health Corporation Stock Up 9.5%

On Monday, shares of ZEPP traded near $4.49. The stock has experienced fluctuations within a 52-week range, with a low of $2.50 and a high of $6.75. Investors have been closely watching the stock, given its recent activity and the adjustments made by major institutional investors.

Analysts Set New Price Targets

Citi maintained its 'buy' rating for ZEPP, setting a price target of $3.10 on August 21, 2023. This reflects continued optimism from analysts despite the recent insider sales and market fluctuations.

Insider Buying and Selling at Zepp Health Corporation

Aside from his recent sale, Cheng Deng also bought back 366,000 shares on April 1, 2026. On the same day as his latest sale, he sold an additional 9,836 shares at an average price of $4.61. These transactions were not conducted under a Rule 10b5-1 plan, indicating they were not pre-planned.

About ZEPP

ZEPP is a company that operates in the technology sector, focusing on smart wearables and related technology products. The company is known for its innovative approach to integrating technology and health monitoring. ZEPP is headquartered in China and continues to expand its product offerings globally.

Bottom Line

The recent sale by CFO Cheng Deng and the activity from institutional investors highlight the dynamic nature of ZEPP's stock. Investors often track such insider transactions and institutional movements to gauge market sentiment. While these filings provide a snapshot of past actions, they may not reflect current or future positions.